Risk-adapted MRD-directed therapy for young adults with acute myeloid leukemia: 6-year update of the GIMEMA AML1310 trial.

ABSTRACT:

SUBMITTER: Venditti A 

PROVIDER: S-EPMC11375254 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature